Hybio Pharmaceutical Co., Ltd. (SHE:300199)

Market Cap	18.34B +60.4%
Revenue (ttm)	898.10M +121.7%
Net Income	-67.50M
EPS	-0.08
Shares Out	883.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,383,214
Average Volume	37,467,220
Open	19.61
Previous Close	19.50
Day's Range	19.36 - 20.88
52-Week Range	10.50 - 31.19
Beta	0.76
RSI	64.95
Earnings Date	Apr 29, 2026

About Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermedia...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 1,035
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300199

Financial Performance

In 2024, Hybio Pharmaceutical's revenue was 590.20 million, an increase of 36.82% compared to the previous year's 431.38 million. Losses were -173.65 million, -66.21% less than in 2023.